Does the media refer more to TXG or TWST?

In the previous week, Twist Bioscience had 19 more articles in the media than 10x Genomics. MarketBeat recorded 30 mentions for Twist Bioscience and 11 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.45 beat Twist Bioscience's score of 0.28 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 1 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Twist Bioscience 12 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DNA or TWST?

In the previous week, Twist Bioscience had 10 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 29 mentions for Twist Bioscience and 19 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.29 beat Twist Bioscience's score of 0.29 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Twist Bioscience 13 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MTD or TWST?

In the previous week, Twist Bioscience had 20 more articles in the media than Mettler-Toledo International. MarketBeat recorded 29 mentions for Twist Bioscience and 9 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 0.31 beat Twist Bioscience's score of 0.29 indicating that Mettler-Toledo International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Twist Bioscience 13 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, TWST or RVTY?

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $431.80M 23.20 -$77.67M -$2.22 N/A Revvity $2.86B 6.02 $241.20M $2.10 73.43

Does the media favor TWST or RVTY?

In the previous week, Twist Bioscience had 23 more articles in the media than Revvity. MarketBeat recorded 30 mentions for Twist Bioscience and 7 mentions for Revvity. Revvity's average media sentiment score of 0.46 beat Twist Bioscience's score of 0.28 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 12 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Revvity 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, TWST or MEDP?

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $431.80M 23.20 -$77.67M -$2.22 N/A Medpace $2.78B 6.14 $451.12M $17.06 35.88

Is TWST or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -31.66% -28.64% -19.94% Medpace 17.67% 110.15% 24.84%

Does the media prefer TWST or MEDP?

In the previous week, Twist Bioscience had 24 more articles in the media than Medpace. MarketBeat recorded 30 mentions for Twist Bioscience and 6 mentions for Medpace. Medpace's average media sentiment score of 0.68 beat Twist Bioscience's score of 0.28 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 12 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Twist Bioscience (TWST) Competitors

$159.78 +7.73 (+5.08%)

Closing price 04:00 PM Eastern

Extended Trading

$162.14 +2.36 (+1.48%)

As of 07:58 PM Eastern

Compare

TWST vs. TXG, DNA, MTD, RVTY, and MEDP

Should you buy Twist Bioscience stock or one of its competitors? Twist Bioscience's main competitors and comparable companies include 10x Genomics (TXG), Ginkgo Bioworks (DNA), Mettler-Toledo International (MTD), Revvity (RVTY), and Medpace (MEDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Twist Bioscience compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Twist Bioscience (NASDAQ:TWST) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

10x Genomics has a net margin of -12.18% compared to Twist Bioscience's net margin of -31.66%. 10x Genomics' return on equity of -9.33% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Twist Bioscience	-31.66%	-28.64%	-19.94%

10x Genomics presently has a consensus target price of $58.60, indicating a potential downside of 27.34%. Twist Bioscience has a consensus target price of $128.17, indicating a potential downside of 19.79%. Given Twist Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Twist Bioscience is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28
Twist Bioscience	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

In the previous week, Twist Bioscience had 19 more articles in the media than 10x Genomics. MarketBeat recorded 30 mentions for Twist Bioscience and 11 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.45 beat Twist Bioscience's score of 0.28 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Twist Bioscience	12 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics has higher revenue and earnings than Twist Bioscience. 10x Genomics is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	16.35	-$43.54M	-$0.59	N/A
Twist Bioscience	$431.80M	23.20	-$77.67M	-$2.22	N/A

10x Genomics has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

10x Genomics beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	4.50	-$312.76M	-$5.01	N/A
Twist Bioscience	$376.57M	25.32	-$77.67M	-$2.22	N/A

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ginkgo Bioworks currently has a consensus target price of $6.33, suggesting a potential downside of 44.32%. Twist Bioscience has a consensus target price of $128.17, suggesting a potential downside of 15.71%. Given Twist Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Twist Bioscience is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Twist Bioscience	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -259.96%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Twist Bioscience	-31.66%	-28.64%	-19.94%

In the previous week, Twist Bioscience had 10 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 29 mentions for Twist Bioscience and 19 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.29 beat Twist Bioscience's score of 0.29 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Twist Bioscience	13 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Mettler-Toledo International has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	7.60	$869.19M	$44.43	34.38
Twist Bioscience	$376.57M	25.32	-$77.67M	-$2.22	N/A

95.1% of Mettler-Toledo International shares are held by institutional investors. 0.7% of Mettler-Toledo International shares are held by company insiders. Comparatively, 3.1% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mettler-Toledo International has a net margin of 21.91% compared to Twist Bioscience's net margin of -31.66%. Twist Bioscience's return on equity of -28.64% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Mettler-Toledo International presently has a consensus price target of $1,459.54, indicating a potential downside of 4.45%. Twist Bioscience has a consensus price target of $128.17, indicating a potential downside of 15.71%. Given Mettler-Toledo International's higher probable upside, equities analysts clearly believe Mettler-Toledo International is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.27
Twist Bioscience	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

In the previous week, Twist Bioscience had 20 more articles in the media than Mettler-Toledo International. MarketBeat recorded 29 mentions for Twist Bioscience and 9 mentions for Mettler-Toledo International. Mettler-Toledo International's average media sentiment score of 0.31 beat Twist Bioscience's score of 0.29 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	13 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mettler-Toledo International has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

Summary

Mettler-Toledo International beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Revvity?

Twist Bioscience (NASDAQ:TWST) and Revvity (NYSE:RVTY) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, Twist Bioscience had 23 more articles in the media than Revvity. MarketBeat recorded 30 mentions for Twist Bioscience and 7 mentions for Revvity. Revvity's average media sentiment score of 0.46 beat Twist Bioscience's score of 0.28 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	12 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revvity	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Revvity shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Revvity has a net margin of 8.16% compared to Twist Bioscience's net margin of -31.66%. Revvity's return on equity of 8.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Revvity	8.16%	8.34%	5.01%

Twist Bioscience presently has a consensus price target of $128.17, suggesting a potential downside of 19.79%. Revvity has a consensus price target of $120.50, suggesting a potential downside of 21.86%. Given Twist Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Revvity	0 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.26

Revvity has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	23.20	-$77.67M	-$2.22	N/A
Revvity	$2.86B	6.02	$241.20M	$2.10	73.43

Twist Bioscience has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Revvity has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Revvity beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Medpace?

Twist Bioscience (NASDAQ:TWST) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Medpace has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$431.80M	23.20	-$77.67M	-$2.22	N/A
Medpace	$2.78B	6.14	$451.12M	$17.06	35.88

Twist Bioscience currently has a consensus target price of $128.17, suggesting a potential downside of 19.79%. Medpace has a consensus target price of $607.73, suggesting a potential downside of 0.71%. Given Medpace's higher probable upside, analysts clearly believe Medpace is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

In the previous week, Twist Bioscience had 24 more articles in the media than Medpace. MarketBeat recorded 30 mentions for Twist Bioscience and 6 mentions for Medpace. Medpace's average media sentiment score of 0.68 beat Twist Bioscience's score of 0.28 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	12 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Twist Bioscience has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Medpace has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

78.0% of Medpace shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Medpace has a net margin of 17.67% compared to Twist Bioscience's net margin of -31.66%. Medpace's return on equity of 110.15% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.

Get Twist Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TWST vs. The Competition

Export

Metric	Twist Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.53B	$10.42B	$7.16B	$13.21B
Dividend Yield	N/A	1.45%	2.53%	20.71%
P/E Ratio	-71.97	32.42	274.13	26.16
Price / Sales	26.61	107.04	581.78	94.37
Price / Cash	N/A	27.23	76.38	53.09
Price / Book	20.38	6.49	11.21	6.34
Net Income	-$77.67M	$56.67B	$3.50B	$381.90M
7 Day Performance	-15.31%	-1.09%	-0.84%	-1.39%
1 Month Performance	27.29%	8.84%	-5.42%	-4.31%
1 Year Performance	401.03%	28.78%	4.38%	-0.35%

Twist Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TWST Twist Bioscience	2.0527 of 5 stars	$159.78 +5.1%	$128.17 -19.8%	+363.7%	$9.53B	$376.57M	N/A	979	Analyst Forecast Insider Trade
TXG 10x Genomics	1.9669 of 5 stars	$77.28 +1.6%	$58.60 -24.2%	+540.3%	$9.92B	$642.82M	N/A	1,178	Analyst Forecast
DNA Ginkgo Bioworks	1.4417 of 5 stars	$11.38 -0.8%	$6.33 -44.3%	-29.3%	$772.39M	$170.15M	N/A	485	News Coverage Gap Up
MTD Mettler-Toledo International	2.7517 of 5 stars	$1,527.52 -0.4%	$1,459.54 -4.5%	+15.0%	$30.73B	$4.03B	34.38	18,100	News Coverage Analyst Forecast
RVTY Revvity	2.5837 of 5 stars	$152.29 -0.9%	$120.50 -20.9%	+65.7%	$17.14B	$2.86B	72.52	11,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TWST) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Competitors

TWST vs. TXG, DNA, MTD, RVTY, and MEDP

How does Twist Bioscience compare to 10x Genomics?

Summary

How does Twist Bioscience compare to Ginkgo Bioworks?

Summary

How does Twist Bioscience compare to Mettler-Toledo International?

Summary

How does Twist Bioscience compare to Revvity?

Summary

How does Twist Bioscience compare to Medpace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Competitors

TWST vs. TXG, DNA, MTD, RVTY, and MEDP

How does Twist Bioscience compare to 10x Genomics?

Is TXG or TWST more profitable?

Do analysts prefer TXG or TWST?

Does the media refer more to TXG or TWST?

Which has higher earnings & valuation, TXG or TWST?

Which has more volatility & risk, TXG or TWST?

Do institutionals and insiders believe in TXG or TWST?

Summary

How does Twist Bioscience compare to Ginkgo Bioworks?

Which has more risk and volatility, DNA or TWST?

Which has stronger earnings & valuation, DNA or TWST?

Do institutionals and insiders hold more shares of DNA or TWST?

Do analysts prefer DNA or TWST?

Is DNA or TWST more profitable?

Does the media favor DNA or TWST?

Summary

How does Twist Bioscience compare to Mettler-Toledo International?

Which has better valuation and earnings, MTD or TWST?

Do insiders & institutionals believe in MTD or TWST?

Is MTD or TWST more profitable?

Do analysts prefer MTD or TWST?

Does the media refer more to MTD or TWST?

Which has more risk and volatility, MTD or TWST?

Summary

How does Twist Bioscience compare to Revvity?

Does the media favor TWST or RVTY?

Do insiders and institutionals have more ownership in TWST or RVTY?

Is TWST or RVTY more profitable?

Do analysts recommend TWST or RVTY?

Which has preferable earnings and valuation, TWST or RVTY?

Which has more volatility and risk, TWST or RVTY?

Summary

How does Twist Bioscience compare to Medpace?

Which has stronger earnings and valuation, TWST or MEDP?

Do analysts prefer TWST or MEDP?

Does the media prefer TWST or MEDP?

Which has more risk and volatility, TWST or MEDP?

Do insiders and institutionals hold more shares of TWST or MEDP?

Is TWST or MEDP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools